Mammary Cell News 8.29 July 28, 2016 | |
| |
TOP STORYBRCA1185delAG Tumors May Acquire Therapy Resistance through Expression of RING-Less BRCA1 The authors investigated mammary tumorigenesis and therapy sensitivity in mice carrying the Brca1185stop and Brca15382stop alleles, which respectively mimic the two most common BRCA1 founder mutations, BRCA1185delAG and BRCA15382insC. Both the Brca1185stop and Brca15382stop mutations predisposed animals to mammary tumors, but Brca1185stop tumors responded markedly worse to homologous recombination deficiency -targeted therapy than did Brca15382stop tumors. [J Clin Invest] Full Article | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHIL-17E Synergizes with EGF and Confers In Vitro Resistance to EGFR-Targeted Therapies in TNBC Cells The authors investigated whether IL-17E promotes triple-negative breast cancers (TNBCs) resistance to anti-epidermal growth factor receptor (EGFR) therapeutic agents by exploring the link between the IL-17E/IL-17E receptor axis and EGFR signaling. [Oncotarget] Full Article Loss of progesterone-receptors (PR) expression is associated with breast cancer progression. Researchers provide evidence that OHPg/PR-B through Beclin-1 evoke autophagy-senescence transition, in breast cancer cells. [Oncotarget] Full Article Researchers aimed to evaluate the clinical utility of a novel rapid dual in-situ hybridization method developed to facilitate hybridization. The method takes advantage of the non-contact mixing effect of an alternating current electric field. [Sci Rep] Full Article Scientists demonstrated that there can be marked cellular and phenotypic heterogeneity in a single batch of the human breast adenocarcinoma cell line MCF-7 obtained directly from a cell bank that are invisible with the usual cell authentication by short tandem repeat markers. [Sci Rep] Full Article Investigators showed that microRNA (miRNA)-9, upregulated in various breast cancer cell lines and identified as pro-metastatic miRNA, affects the properties of human breast fibroblasts, enhancing the switch to cancer-associated fibroblasts phenotype, thus contributing to tumor growth. [Cell Death and Dis] Full Article Reassessment of HER2, estrogen (ER) and progesterone (PR) markers at the time of disease progression might help to optimize treatment decisions. In this context, characterization of circulating tumor cells (CTCs) could be of relevance since metastatic tissue may be difficult to obtain for repeated analysis. Researchers compared HER2/ER/PR expression profiles of primary tumors, metastases and CTCs. [BMC Cancer] Full Article The extracellular subpopulation of syntaxin-4, extruded in response to the induction of differentiation or apoptosis in mammary epithelial cells, was detected. Using a tetracycline-repressive transcriptional system and clonal mammary epithelial cells, SCp2, scientists found that the expression of cell surface syntaxin-4 elicits epithelial-mesenchymal transition-like cell behaviors. [J Cell Biochem] Abstract Scientists investigated SerpinB5 (serine protease inhibitor) expression, subcellular localization and phosphorylation in different stages of the mouse mammary gland development and the signaling pathway involved. They showed that SerpinB5 is first detected in late pregnancy, reaches its highest levels in lactation and remains at constant levels during post-lactational regression. [PLoS One] Full Article CLINICAL RESEARCHThe Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis To inform the development of other effective treatments researchers report summary estimates of efficacy of trastuzumab on survival and tumor volume in animal models of breast cancer. [PLoS One] Full Article | |
| |
REVIEWSImproving Early Diagnosis of Symptomatic Cancer Much time, effort and investment goes into the diagnosis of symptomatic cancer, with the expectation that this approach brings clinical benefits. This investment of resources has been particularly noticeable in the United Kingdom, which has, for several years, appeared near the bottom of international league tables for cancer survival in economically developed countries. In this review, the authors examine expedited diagnosis of cancer from four perspectives. [Nat Rev Clin Oncol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSHalozyme Therapeutics, Inc. announced that Eisai Inc. has dosed the first patient in a collaborative Phase Ib/II clinical trial to assess whether Eisai’s eribulin mesylate in combination with Halozyme’s investigational drug PEGPH20, can improve overall response rate as compared with eribulin alone as a therapy in women with advanced or metastatic, high-hyaluronan HER2-negative breast cancer. [Halozyme Therapeutics, Inc.] Press Release Puma Biotechnology, Inc. announced updated results from the Phase III clinical trial of Puma’s investigational drug PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab in women with early stage HER2-positive breast cancer. [Puma Biotechnology, Inc.] Press Release Puma Biotechnology, Inc. has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab-based therapy. [Puma Biotechnology, Inc.] Press Release | |
| |
POLICY NEWSMajor Review Calls Time on Gaming in UK Research Assessment The UK’s mammoth periodic audit of its research is set for a shake-up that could change the way universities hire academics – and might also encourage scientists to spend more time on public engagement. [Nature News] Editorial More Support for Clinical Trials in Children A cancer diagnosis is a shock, but adults with the disease can take some comfort in the numerous treatments available to them — both through clinical trials and as drugs that are already on the market. Children cannot. [Nature] Editorial Trump vs Clinton: Worlds Apart on Science Presidential candidates begin to make clear their stark differences on climate change, energy production and stem-cell research. [Nature News] Editorial Europe Overhauls Rules for ‘First-In-Human’ Trials in Wake of French Disaster The European Union is beefing up protections for volunteers in Phase I clinical trials in the wake of a disastrous clinical study in Rennes, France, that resulted in the death of one volunteer and the hospitalization of five others. The European Medicines Agency (EMA) in London announced in a “concept paper” that it wants to improve strategies to identify and reduce risks in “first-in-human” studies on healthy volunteers. EMA is asking for input from stakeholders. [ScienceInsider] Editorial | Article Chinese Scientists to Pioneer First Human CRISPR Trial Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique. A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. [Nature News] Editorial Scientific Literature: Information Overload Recent bibliometrics show that the number of published scientific papers has climbed by 8–9% each year over the past several decades. In the biomedical field alone, more than 1 million papers pour into the PubMed database each year — about two papers per minute. [Nature Careers] Editorial Exactly one month after Britain’s momentous decision to leave the European Union, around 4500 scientists and friends of science will assemble in Manchester, UK, for the opening of the EuroScience Open Forum, Europe’s largest interdisciplinary research conference. [Science] Editorial
| |
EVENTSNEW European Society for Medical Oncology (ESMO) Asia 2016 Congress Visit our events page to see a complete list of events in the mammary cell community.
| |
JOB OPPORTUNITIESNEW Robert Stowell Chair – Experimental Pathology (University of California, Davis) NEW Lead Bioinformatitian – Cancer-Related Genes and Targeted Drugs (Institute of Cancer Research) Scientific Director – Global Medical Affairs (Celgene Corporation) Research Assistant – Role of Platelets in Breast Cancer Metastases (Jagiellonian University) Postdoctoral Position – Metastatic Reactivaction of Cancer (MD Anderson Cancer Center) Scientific Director – Oncology (Merck) Postdoctoral Fellow – Various Projects (National University of Singapore) Postdoctoral Fellow – Breast Cancer Monitoring through Digital Imaging (University Rovira i Virgili) Postdoctoral Researcher – Basic & Translational Breast Cancer Research (Northwestern University) Postdoctoral Associate – Premalignant Progression to Invasive Breast Cancer (Tulane Medical School) Postdoctoral Fellow – Molecular Genetics of Breast Cancer (German Cancer Research Centre) Postdoctoral Fellowship – Cancer Research (German Cancer Research Center) Postdoctoral Fellow – Proteogenomic Bioinformatics of Breast Cancer (Lund University) PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.29 | Jul 28 2016